A Systematic Framework for the Construction of Optimal Complete Complementary Codes

The complete complementary code (CCC) is a sequence family with ideal correlation sums which was proposed by Suehiro and Hatori. Numerous literatures show its applications to direct-spread code-division multiple access (DS-CDMA) systems for inter-channel interference (ICI)-free communication with improved spectral efficiency. In this paper, we propose a systematic framework for the construction of CCCs based on $N$-shift cross-orthogonal sequence families ($N$-CO-SFs). We show theoretical bounds on the size of $N$-CO-SFs and CCCs, and give a set of four algorithms for their generation and extension. The algorithms are optimal in the sense that the size of resulted sequence families achieves theoretical bounds and, with the algorithms, we can construct an optimal CCC consisting of sequences whose lengths are not only almost arbitrary but even variable between sequence families. We also discuss the family size, alphabet size, and lengths of constructible CCCs based on the proposed algorithms

Full MAC System Demonstration of Extended 10G-EPON Uplink with 512 ONU Splits Access Span via Burst-Mode SOA and Enhanced-FEC combined with Burst-Mode 3R

This first Extended 10G-EPON uplink system test achieved the largest access span loss of 37 dB supporting 512 ONU splits over 25 km with an enlarged loss budget of 51.2 dB via burst-mode SOA, E-FEC and burst-mode 3R

R-mini CHP in ≥80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol

In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years